Clostridium butyricum live tablets prevents hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in portal hypertension: a randomized controlled study

INTERVENTION: Clostridium butyricum group:Clostridium butyricum 2 tablets/time 3 times/day; Lactulose 15ml/time, 3 times/day;Lactulose group:Lactulose 15ml/time, 3 times/day; CONDITION: hepatic encephalopathy (HE), portal hypertension PRIMARY OUTCOME: Incidence of hepatic encephalopathy; SECONDARY OUTCOME: Time of occurrence of hepatic encephalopathy;Adverse reaction rate;Transplant free survival;Gut microbiota;Metabolomics;Laboratory outcome;Imaging results; INCLUSION CRITERIA: 1. Aged 18‐70 years, no gender limit. 2. Patients treated with TIPS for portal hypertension (esophageal fundus variceal bleeding and/or recurrent chest/ascites) with or without cirrhosis. 3. Sign the informed consent form.